Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: Improved prognosis in the era of highly active antiretroviral therapy

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 7, 2003, Pages 673-677

  Santin, M ^a   Alcaide, F ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Highly active antiretroviral therapy; HIV 1; M. kansasii

Indexed keywords

ANTIRETROVIRUS AGENT; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; STREPTOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM KANSASII; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME SERIES ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0037774731     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bloch K C, Zwerling L, Pletcher M J, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129: 698-704.
2. Sherer R, Sable R, Sonnenberg M, et al. Disseminated infection with Mycobacterium kansasii in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 710-712.
3. Bamberger D M, Driks M R, Gupta M R, et al. Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City. Clin Infect Dis 1994; 18: 395-400.
4. Witzig R S, Fazal B A, Mera R M, et al. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995; 21: 77-85.
5. Campo R E, Campo C E. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1233-1238.
6. Palella F J Jr, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
7. Kunin C M. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 (Suppl 1): S3-S13.
8. American Thoracic Society. Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156 (2 Pt 2): S1-S25.
9. Gullans C R, Sr. Digestion-decontamination procedures. In: Isenberg H D, ed. Clinical microbiology procedures handbook. Washington, DC: ASM Press, 1992: p 3.4.1-3.4.14.
10. Nolte F S, Metchock B. Mycobacterium. In: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, eds. Manual of clinical microbiology. 6th ed. Washington, DC: ASM Press;1995. pp 400-437.
11. Kirk O, Gatell J M, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. Am J Respir Crit Care Med 2000; 162: 865-872.
12. Leonard M K, Larsen N, Drechsler H, et al. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 2002; 34: 1002-1007.
13. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 126: 326-331.
14. Jones J L, Hanson D L, Dworkin M S, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The adult/adolescent spectrum of HIV disease group. Int J Tuberc Lung Dis 2000; 4: 1026-1031.
15. Gonzalez-Montaner L J, Natal S, Yongchaiyud P, Olliaro P, Rifabutin Study Group. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampin. Tubercle Lung Dis 1994; 75: 341-347.
16. Schwander S, Rush-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampin in the treatment of HIV-1 associated tuberculosis: a single blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210-218.
17. Narita M, Stambaugh J J, Hollender E S, Jones D, Pitchenik A E, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-783.
18. Santin M, Barberá J, Alcaide F, Podzamczer D, Rufí G. Treatment of tuberculosis among HIV-infected patients in the era of highly active antiretroviral therapy: clinical experience with Rifabutin. Istanbul, Turkey: 11th European Congress of Clinical Microbiology and Infectious Diseases. April, 1-4, 2001. (Abstract o41).